Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15813555 | 0.91 | HTR2C (0.53) | HTR2CHTR2BHTR2AEZH2LRRK2 | |
| SCHEMBL20499628 | 0.75 | EZH2 (0.45) | HTR2CHTR2BHTR2AEZH2KDM4E | |
| SCHEMBL19229259 | 0.75 | KDR (0.40) | KDRLRRK2KDM4EALDH1A1MAPT | |
| SCHEMBL10158541 | 0.74 | KDM4E (0.53) | HTR2CHTR2BHTR2AEZH2KDM4E | |
| SCHEMBL14660757 | 0.74 | KDM4E (0.50) | HTR2CHTR2BHTR2AKDM4EALDH1A1 | |
| SCHEMBL15814243 | 0.73 | PARP10 (0.41) | HTR2CHTR2BHTR2AKDM4EALDH1A1 | |
| SCHEMBL15814852 | 0.73 | PARP10 (0.41) | HTR2CHTR2BHTR2AKDRKDM4E | |
| SCHEMBL22135686 | 0.72 | PARP10 (0.41) | HTR2CHTR2BHTR2AEZH2PARP1 | |
| SCHEMBL14854352 | 0.71 | DYRK1A (0.43) | HTR2CHTR2BHTR2AALDH1A1LMNA | |
| SCHEMBL17372871 | 0.71 | ACHE (0.46) | HTR2CHTR2BHTR2AEZH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | HTR2C 3482/4885HTR2B 3560/4885HTR2A 3810/4885 |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | HTR2C 3482/4885HTR2B 3560/4885HTR2A 3810/4885 |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | CCNY, MLX, NFXL1 | HTR2C 3482/4885HTR2B 3560/4885HTR2A 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.